Unforeseen developments  by unknown
Innovations 703 
Unforeseen 
developments 
Ontogeny, Inc. 
For pharmaceutical companies the 
word ‘development’ is no longer just 
a suffix to the words ‘research and’. A 
small but vociferous group of 
companies, including Ontogeny, Inc. 
of Cambridge, hlassachusetts, has 
been promoting the joys of fruit flies, 
worms and mice, and the proteins 
that drive their development. 
“The focus [for Ontogeny] is to 
identify the key molecules that are 
involved in building up the body, 
and to use them to reactivate the 
same processes in the adult,” says 
Doros Platika, President and CEO of 
Ontogeny. Platika is convinced that 
many remodeling processes -which 
could potentially cure degenerative 
diseases - are merely dormant, 
waiting for the correct inducing 
signal. One example he gives is 
angiogenesis: when a clot blocks one 
of the heart’s blood vessels, the body 
cannot reconstruct a new vessel, and 
yet a tumor producing the right 
factors can coax blood vessels to grow 
in its direction. 
Hedgehogs as pharmaceuticals 
The key proteins for Ontogeny are 
the three hedgehogs: Sonic (Shh), 
Indian (Ihh), and Desert (Dhh). 
Hedgehog (Hh) was first discovered 
in the fruit fly, as a molecule that 
defines the front and back of body 
segments. The discovery of the three 
mammalian genes was announced in 
1993 by Philip Ingham, then at the 
Imperial Cancer Research Fund in 
Oxford, and Andrew McMahon of 
Harvard University. (Both scientists 
are now members of Ontogeny’s 
scientific advisory board.) 
Innovations is a monthly column that surveys 
the science done at biotechnology 
companies. 
If expressed appropriately the 
three proteins can substitute for each 
other, but, in wild-type animals, their 
distinct distributions result in unique 
activities. Shh controls the polarity of 
limb growth, directs the 
development of neurons in the 
ventral neural tube, and patterns the 
somites. Ihh controls one type of 
bone development, and Dhh is 
necessary for spermiogenesis. 
The sound of nerve regrowth 
With the help of Biogen, Inc. 
(Cambridge, MA), Ontogeny hopes 
to use Shh as a treatment for various 
degenerative disorders of the nervous 
system. The aim is to restore the lost 
neurons, whether it be basal forebrain 
neurons (Alzheimer’s disease), motor 
neurons (amyotrophic lateral sclerosis 
(ALS) or Lou Gehrig’s disease), or 
dopaminergic neurons of the 
substantia nigra (Parkinson’s disease). 
“[Shh] is important enough that it 
justifies going for it in a major way,” 
says Ali Hemmati-Brivanlou of 
Rockefeller University. He believes, 
however, that timing may be critical. 
Tissues that respond to molecules 
like Shh in the embryo will not 
always respond in the adult. 
Ontogeny is off to a promising 
start with Parkinson’s disease. They 
recently reported that Shh promotes 
the survival of cultured dopaminergic 
neurons and neurons that produce 
the inhibitory neurotransmitter 
GABA. The latter neurons could 
keep the substantia nigra 
neurologically quiet while it is 
rebuilding itself, further protecting 
the critical dopaminergic neurons. 
At least in a culture dish, Shh 
prevents the death of dopaminergic 
neurons after application of MPP+, a 
highly specific neurotoxin. The 
designer drug MPP+ - a distant 
relative of speed - causes a 
temporary high by killing 
dopaminergic neurons and so 
releasing the neurotransmitter 
dopamine. But as soon as a day later, 
severe Parkinson’s disease sets in. 
Moving from the laboratory to the 
clinic will not be easy. “Any drug 
that addresses the brain has a 
distribution problem right off the 
bat,” admits Platika, and for Shh the 
only solution at present is holes in 
the skull. Ontogeny is proceeding 
with Shh animal trials, using direct 
injection into the brain, and a 
decision on human trials will be 
made in the first half of 1998. 
Amgen: the company to emulate 
Amgen, Inc. (Thousand Oaks, CA) is 
already involved in clinical trials of 
glial cell line-derived neurotrophic 
factor (GDNF) for Parkinson’s 
GDNF restores motor performance 
in animal models of the disease. 
The economic leader in 
developmental inducing molecules, 
Amgen owns two molecules that 
between them generate -$Z billion 
in revenue per year. Epogen 
(erythropoietin) generates red blood 
cells in the face of renal failure, and 
Neupogen (granulocyte-colony 
stimulating factor) stimulates the 
production of blood-clotting 
neutrophils after chemotherapy. 
Regeneron Pharmaceuticals 
(Tarrytown, NY) is working with 
Amgen to test neurotrophin-3 for 
diabetic neuropathy, and Genentech 
(South San Francisco, CA) is trying 
out nerve growth factor for the same 
application. Regeneron has stopped 
trials of ciliary neurotrophic factor 
(CNTF) and subcutaneous brain- 
derived neurotrophic factor (BDNF), 
although trials continue for the 
injection of BDNF into the central 
nervous system of ALS patients. 
Boning up on fracture repair 
Lots of people break bones, and lots 
of them do it in such spectacular 
ways that more than a plaster cast is 
needed. Ihh is a molecule that could 
give regrowing bone a helping hand. 
Bones grow by one of two 
mechanisms. Membranous bones 
such as the skull and clavicle form 
when fibroblasts develop directly 
into osteoblasts. In endochondral 
ossification, however, the cells that 
are the precursors of long bones first 
develop into cartilage. 
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Last year, Clifford Tabin (of 
Harvard Medical School and the 
Ontogeny scientific advisory board) 
reported that Ihh keeps 
endochondral bone precursors in a 
proliferating, undifferentiated state. 
When differentiation occurs too early 
there is a loss of bone mass. “When 
you knock out IA/z,” says Platika, 
“you get a pretty nicely formed 
skeleton but in miniature. It’s the 
bonsai of skeletons.” 
After a fracture, the healing of 
membranous bones and 
endochondral bones is identical. But 
broken bones that are immobilized 
and closely apposed heal by the 
membranous route, whereas mobile 
or separated bone fragments rejoin 
by endochondral growth. Tabin 
believes that Ihh could aid both 
forms of repair. Ihh turns on the 
production of several of the bone 
morphogenetic proteins (BMPs), 
which can directly create ectopic 
bone. And Ihh could be used to 
delay the premature differentiation 
that often occurs in fractures that 
cannot be completely set, thus 
encouraging full closure of the gap 
between bones. 
Beware of false bone healers 
The BMPs are not only the 
mediators of the Ihh signal, but also 
competitors for the same 
pharmaceutical niche. Genetics 
Institute (Cambridge, MA) and 
Creative Biomolecules (Hopkinton, 
MA) have begun clinical trials with 
BMP-2 and osteogenic protein-l 
(OP-1 or BMP-7), respectively. 
Starting from behind, Ihh will need 
to show a clear clinical advantage 
over the BMPs to warrant further 
development. 
“The burden of proof is still on 
us,” admits Platika. But he hopes 
that Ihh, as master controller, will 
prove superior. “By stimulating at 
the top of the cascade - by pushing 
down the first domino - everything 
happens at the appropriate time in 
the appropriate way,” he says. Rik 
Derynck, a growth-factor researcher 
at the University of California, San 
Francisco, says that the pathway’s 
complexity may make such 
considerations irrelevant. “It’s a little 
bit like a Swiss watch,” he says. “If 
you turn one thing everything will 
turn.” 
The complexity of bone 
formation makes the success of Ihh 
hard to predict. Monetary support is, 
however, now in place following a 
deal with Boehringer Mannheim. 
A reproductive desert 
Harvard’s McMahon reported in 
Current Biology last year that Dhh is 
produced by the Sertoli cells in the 
testes and is required for the 
maturation of sperm. This has 
sparked Ontogeny’s interest, and 
Platika predicts that both Dhh (as a 
fertility drug) and an inhibitor of 
Dhh (as a contraceptive) could be 
useful pharmaceuticals, This project 
is at an early stage: Platika does not 
know, for example, if inhibition of 
Dhh starting in the adult would 
block sperm production. 
Other early-stage projects 
include the transplantation of 
pancreatic precursor cells to treat 
diabetes, and alteration of elements 
downstream of Hh to target basal 
cell carcinoma (BCC). A non- 
metastatic but potentially disfiguring 
skin cancer, BCC is the most 
common cancer known, and its 
incidence is rising from increased 
sun exposure. Current treatment 
involves surgery. Ontogeny has the 
rights to treatments that boost the 
activity of Patched, the Hh receptor 
defective in BCC, but a more logical 
treatment may be inhibitors of 
Smoothened, the protein 
downstream of Patched that keeps 
the Hh pathway turned off. Rights 
to the latter treatments have not 
been resolved. 
Ontogeny is seeking to decrease 
its reliance on the hedgehog proteins 
with OntoScreen, a series of assays 
that determine the level, timing and 
location of the expression of genes. 
Genes that show very specific 
expression patterns are investigated 
for possible roles in development. 
An excellent evolutionary approach 
One company that is young and yet 
not wedded to any one set of protein 
targets is Exelixis, Inc., which has 
recently moved to South San 
Francisco, CA. “I think Exelixis is 
going to be one of the best biotech 
companies,” says Hemmati-Brivanlou. 
“For the first time a company has 
adopted an academic approach and is 
making use of evolution.” 
Exelixis uses developmental 
model organisms - fruit flies, 
worms, mice and frogs -to flesh out 
important cellular pathways. For 
example, a transgenic fly expressing 
the human oncogene ras in the eye 
has deformed eyes. Fly mutations 
that increase or decrease this effect 
can be easily identified and are often 
in genes that are part of the was 
pathway. The aim is to identify 
proteins, such as enzymes and 
G-protein-coupled receptors, that are 
better targets for chemical inhibitors. 
Exelixis will pursue multiple 
targets simultaneously, developing 
these projects to the point that animal 
and clinical trials can begin before 
selling the project to a pharmaceutical 
company. The starting points for 
mutation screens include the 
presenilins (Alzheimer’s), glutamate 
receptors (excitatory neurotoxicity), 
the cell cycle targets ~21, EZF and 
APC (cancer), the insulin and leptin 
receptors (diabetes and obesity), 
Notch (stem cell development for 
transplants), and netrins (nerve cell 
regeneration). With the speed of 
working with model organisms, says 
Geoffrey Duyk, Chief Scientific 
Officer, “you can get a lot of things 
started with relatively few people.” 
Distortions in a fly eye are a giant 
leap from earlier work on inducing 
molecules. Studying the 
experimentally accessible and 
clinically relevant blood system was 
an obvious start, but, with these new 
companies on the warpath, any 
interesting protein is fair game. 
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